Is Intellia Therapeutics (NTLA) stock a buy or sell?
According to the issued ratings of 20 analysts in the last year, the consensus rating for Intellia Therapeutics stock is Buy based on the current 3 hold ratings and 17 buy ratings for NTLA. The average twelve-month price target for Intellia Therapeutics is $157.88 with a high price target of $252.00 and a low price target of $85.00.
What was the price of The NTLA IPO?
(NTLA) raised $85 million in an initial public offering on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Intellia Therapeutics' stock symbol?
Where can I buy NTLA shares?
Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is it a good time to buy NTLA now?
Healthcare sector seems bullish overall. Lots of stocks within this sector have bullish bias as well. NTLA have a pretty well defined ABCDE Triangle pattern, and any time now is a good time to enter. Stop loss below the low of C i. e. around $140. Disclaimer: I'm not giving any trading and investing advice. I'm just sharing my chart observations.
Should I buy NTLA stock?
Out of 12 analysts, 4 (33.33%) are recommending NTLA as a Strong Buy, 7 (58.33%) are recommending NTLA as a Buy, 1 (8.33%) are recommending NTLA as a Hold, 0 (0%) are recommending NTLA as a Sell, and 0 (0%) are recommending NTLA as a Strong Sell.
Why is NTLA stock going up?
Is NTLA stock going to rise? Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and NTLA is experiencing buying pressure, which is a positive indicator for future bullish movement.
Why is Intellia Therapeutics stock dropping?
Shares of gene-editing leader Intellia Therapeutics have dropped 35% since late February, when the U.S. Patent and Trademark Office decided it would not grant patents that Intellia relied on in developing treatments for diseases like sickle cell and cancer.
Is Intellia a buy?
Intellia Therapeutics Inc (NASDAQ:NTLA) The 22 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 125.00, with a high estimate of 207.00 and a low estimate of 54.00. The median estimate represents a +97.50% increase from the last price of 63.29.
Will NTLA keep going up?
Based on our forecasts, a long-term increase is expected, the "NTLA" stock price prognosis for 2027-06-30 is 237.021 USD. With a 5-year investment, the revenue is expected to be around +274.03%. Your current $100 investment may be up to $374.03 in 2027. Get It Now!
What does beam therapeutics do?
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts.
Why is Editas stock down?
However, the main factor behind Editas' decline this week appears to be the overall sell-off in biotech stocks.
Is NTLA a buy Zacks?
See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
Should I sell Intellia?
17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 1 hold rating and 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Intellia Therapeutics stock.
Will CRSP stock go up?
Stock Price Forecast The 22 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 108.50, with a high estimate of 220.00 and a low estimate of 46.00. The median estimate represents a +29.55% increase from the last price of 83.75.
Market check: Stocks mixed at open as volatility spikes
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q4 Earnings Expected to Decline
Yahoo Finance's Jared Blikre breaks down how markets opened on Friday.
The Petri Dish: 2seventy rounds out C-suite, Moderna goes global
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia (NTLA) Up on Deal With ONK for Cancer Therapies
The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.
Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer
Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.
Newsflash: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Have Been Trimming Their Revenue Forecasts
Collaboration combines Intellia’s genome editing platform with ONK’s optimized natural killer (NK) cell therapy platform Intellia grants ONK non-exclusive rights to its ex vivo genome editing and LNP delivery technologies and exclusive rights to certain guide RNAs for up to five allogeneic CRISPR-edited NK cell therapies ONK is responsible for the research, clinical development and commercialization of engineered NK cell therapies derived from collaboration Intellia to receive global co-developm.
Premium Research for NTLA
The latest analyst coverage could presage a bad day for Intellia Therapeutics, Inc. ( NASDAQ:NTLA ), with the analysts...
Company Summary
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Who sold NTLA stock?
Cambridge, MA-based Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics.
When will Intellia Therapeutics release its earnings?
NTLA stock was sold by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA. Company insiders that have sold Intellia Therapeutics company stock in the last year include Andrew Schiermeier, Caroline Dorsa, Jean Francois Formela, John M Leonard, Jose E Rivera, and Perry A Karsen.
How much does Intellia Therapeutics make?
Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. View our earnings forecast for Intellia Therapeutics.
